Intracellular sequestration of amiodarone: Role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology

British Journal of Pharmacology

Volumn 157, Issue 8, 2009, Pages 1531-1540

  Morissette, G ^a,b   Ammoury, A ^c   Rusu, D ^a,b   Marguery, M C ^c   Lodge, R ^a   Poubelle, P E ^a,b   Marceau, F ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c CHU PURPAN   (France)

Author keywords

Amiodarone; Macroautophagy; Macrophage; Phospholipidosis; V ATPase

Indexed keywords

2,6 DICHLORO N [3 (1 HYDROXY 1 METHYLETHYL) 2 METHYL 7BENZOFURANYL]BENZAMIDE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE INHIBITOR; AMIODARONE; BAFILOMYCIN A1; CELL PROTEIN; FR 167356; GREEN FLUORESCENT PROTEIN; PARAFFIN; PROTEIN LC3; UNCLASSIFIED DRUG; VACUOLAR ADENOSINE TRIPHOSPHATASE;

ARTICLE; AUTOPHAGY; BIOPSY; CELL STRAIN HEK293; CELL VACUOLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPATHOLOGY; DERMIS; DRUG ANTAGONISM; DRUG DISTRIBUTION; ELECTROPHORETIC MOBILITY; ENDOSOME; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LYSOSOME; MACROPHAGE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN DISCOLORATION; SMOOTH MUSCLE FIBER; TISSUE SECTION;

ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; AUTOPHAGY; BENZAMIDES; BENZOFURANS; CELLS, CULTURED; HUMANS; MACROLIDES; MACROPHAGES; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; VACUOLAR PROTON-TRANSLOCATING ATPASES; VACUOLES;

EID: 70350348659     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00320.x     Document Type: Article

References (39)

1. Adams PC, Sloan P, Morley AR, Holt DW (1986). Peripheral neutrophil inclusion in amiodarone treated patients. Br J Pharmacol 22: 736-738.
2. Ammoury A, Michaud S, Paul C, Prost-Squarcioni C, Alvarez F, Lamant L et al. (2008). Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amio-darone in the skin. Arch Dermatol 144: 92-96.
3. Anderson A, Borlak J (2006). Drug-induced phospholipidosis. FEBS Lett 580: 5533-5540.
4. Basta S, Knoetig SM, Spagnuolo-Weaver M, Allan G, McCullough KC (1999). Modulation of monocytic cell activity and virus susceptibility during differentiation into macrophages. J Immunol 162: 3961-3969.
5. Bowman BJ, McCall ME, Baertsch R, Bowman EJ (2006). A model for the proteolipid ring and bafilomycin/concanamycin-binding site in the vacuolar ATPase of Neurospora crassa. J Biol Chem 281: 31885-31893.
6. Böyum A (1968). Isolation of leukocytes from human blood. Scand J Clin Lab Invest 21 (Suppl. 9): 9-29.
7. Casartelli A, Bonato M, Cristofori P, Crivellente F, Dal Negro G, Masotto I et al. (2003). A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol Toxicol 19: 161-176.
8. Chatelain P, Ferreira J, Laruel R, Ruysschaert JM (1986). Amiodarone induced modifications of the phospholipid physical state. Biochem Pharmacol 35: 3007-3013.
9. Cooper KD, Duraiswamy N, Hammerberg C, Allen E, Kimbrough-Green C, Dillon W et al. (1993). Neutrophils, differentiated mac-rophages, and monocyte/macrophage antigen presenting cells infiltrate murine epidermis after UV injury. J Invest Dermatol 101: 155-163.
10. Delage C, Lagacé R, Huard J (1975). Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can Med Assoc J 112: 1205-1208.
11. Diaz-Guzman E, Mireles-Cabodevila E, Arrosi A, Kanne JP, Budev M (2008). Amiodarone pulmonary toxicity after lung transplantation. J Heart Lung Transplant 27: 1059-1063.
12. Dowson JH, Miller RA, McDonald AT (1986). Autofluorescence emission spectra of dermal lipofuscinosis associated with amiodarone therapy. Arch Dermatol 122: 244-245.
13. Enseleit F, Wyss CA, Duru F, Noll G, Ruschitzka F (2006). The blue man: amiodarone-induced skin discoloration. Circulation 113: e63.
14. Haggie PM, Verkman AS (2009). Unimpaired lysosomal acidification in respiratory epithelial cells in cystic fibrosis. J Biol Chem 284: 7681-7686.
15. Halliday GM, Norval M, Byrne SN, Huang XX, Wolf P (2008). The effects of sunlight on the skin. Drug Discov Today Dis Mech 5: e201-e209.
16. Halliwell WH (1997). Cationic amphiphilic drug-induced phospho-lipidosis. Toxicol Pathol 25: 53-60.
17. Hunyady L, Baukal AJ, Gaborik Z, Olivares-Reyes JA, Bor M, Szaszak M et al. (2002). Differential PI 3-kinase dependence of early and late phases of recycling of the internalized AT1 angiotensin receptor. J Cell Biol 157: 1211-1222.
18. Kabashima K, Nagamachi M, Honda T, Nishigori C, Miyachi Y, Tokura Y et al. (2007). Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors. Lab Invest 87: 49-55.
19. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T et al. (2000). LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19: 5720-5728.
20. Li J, Tripathi RC, Tripathi BJ (2008). Drug-induced ocular disorders. Drug Safety 31: 127-141.
21. Metelitsa AI, Nguyen GK, Lin AN (2005). Imipramine-induced facial pigmentation: case report and literature review. J Cutan Med Surg 9: 341-345.
22. Miller RA, McDonald AT (1984). Dermal lipofuscinosis associated with amiodarone therapy. Report of a case. Arch Dermatol 120: 646-649.
23. Morissette G, Moreau E, C-Gaudreault R, Marceau F (2004). Massive cell vacuolization induced by organic amines such as procainamide. J Pharmacol Exp Ther 310: 395-406.
24. Morissette G, Moreau E, C-Gaudreault R, Marceau F (2005). N-substituted 4-aminobenzamides (procainamide analogs): an assessment of multiple cellular effects concerning ion trapping. Mol Pharmacol 68: 1576-1589.
25. Morissette G, Couture JP, Désormeaux A, Adam A, Marceau F (2008a). Lack of direct interaction between enalaprilat and the kinin B1 receptors. Peptides 29: 606-612.
26. Morissette G, Lodge R, Marceau F (2008b). Intense pseudotransport of a cationic drug mediated by vacuolar ATPase: procainamide-induced autophagic cell vacuolization. Toxicol Appl Pharmacol 228: 364-377.
27. Myers JL, Kennedy JI, Plumb VJ (1987). Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol 18: 349-354.
28. Niikura K, Takano M, Sawada M (2004). A novel inhibitor of vacuolar ATPase, FR167356, which can dissociate between osteoclast vacu-olar ATPase and lysosomal ATPase. Br J Pharmacol 142: 558-566.
29. Nioi P, Perry BK, Wang EJ, Gu YZ, Snyder RD (2007). In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid-based methodologies. Tox Sci 99: 162-173.
30. Pintavorn P, Cook WJ (2008). Progressive renal insufficiency associated with amiodarone-induced phospholipidosis. Kidney Int 74: 1354-1357.
31. Radman M, Tomas D, Situm M, Solter M (2008). What could be expected after fifteen years of amiodarone therapy? Eur J Dermatol 18: 202-203.
32. Reasor MJ, Kacew S (2001). Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med 226: 825-830.
33. Reasor MJ, Hastings KL, Ulrich RG (2006). Drug-induced phospholipi-dosis: issues and future directions. Expert Opin Drug Saf 5: 567-583.
34. Ruangchira-Urai R, Colby TV, Klein J, Nielsen GP, Kradin RL, Mark EJ (2008). Nodular amiodarone lung disease. Am J Surg Pathol 32: 1654-1660.
35. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A et al. (2007). Dronedanone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357: 987-999.
36. Somani P, Simon VA, Temesy-Armos PN, Gross SA, Didio LJ (1986). Amiodarone-associated changes in human neutrophils. Am J Cardiol 57: 666-672.
37. Tapper H, Sundler R. Bafilomycin A1 inhibits lysosomal, phagosomal and plasma membrane H+-ATPase and induces lysosomal enzyme secretion in macrophages. J Cell Physiol 163: 137-144.
38. Vassallo P, Trohman RG (2007). Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298: 1312-1322.
39. Zimetbaum P (2007). Amiodarone for atrial fibrillation. N Engl J Med 356: 935-941.